Cristina Aguayo

Cristina Aguayo

Auto-generated profile, based on publicly available information

Cristina Aguayo

Oncology Department, Infanta Sofía Hospital, Madrid, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2024 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
AMAndres J. Muñoz Martín
Andres J. Muñoz Martín
RLRamón Lecumberri
Ramón Lecumberri
JSJuan Carlos Souto
Juan Carlos Souto
BOBerta Obispo
Berta Obispo
ASAntonio Sanchez
Antonio Sanchez
MHMiguel Ángel Hernández-Presa
Miguel Ángel Hernández-Presa
Purpose: We developed a predictive model to assess the risk of major bleeding (MB) within 6 months of primary venous thromboembolism (VTE) in cancer patients receiving anticoagulant treatment. We also sought to describe the prevalence and incidence of VTE in cancer patients, and to describe clinical characteristics at baseline and bleeding events during follow-up in patients receiving anticoagulants. Methods: This observational, retrospective, and multicenter study used natural language processing and machine learning (ML), to analyze unstructured clinical data from electronic health records from nine Spanish hospitals between 2014 and 2018. All adult cancer patients with VTE receiving anticoagulants were included. Both clinically- and ML-driven feature selection was performed to identify MB predictors. Logistic regression (LR), decision tree (DT), and random forest (RF) algorithms were used to train predictive models, which were validated in a hold-out dataset and compared to the previously developed CAT-BLEED score. Results: Of the 2,893,108 cancer patients screened, in-hospital VTE prevalence was 5.8% and the annual incidence ranged from 2.7 to 3.9%. We identified 21,227 patients with active cancer and VTE receiving anticoagulants (53.9% men, median age of 70 years). MB events after VTE diagnosis occurred in 10.9% of patients within the first six months. MB predictors included: hemoglobin, metastasis, age, platelets, leukocytes, and serum creatinine. The LR, DT, and RF models had AUC-ROC (95% confidence interval) values of 0.60 (0.55, 0.65), 0.60 (0.55, 0.65), and 0.61 (0.56, 0.66), respectively. These models outperformed the CAT-BLEED score with values of 0.53 (0.48, 0.59). Conclusions: Our study shows encouraging results in identifying anticoagulated patients with cancer-associated VTE who are at high risk of MB.

1 March 2013 in Tumori Journal
Verified
Journal Article
Closed access
MSMaría Sereno
María Sereno
MSMaría Merino Salvador
María Merino Salvador
CACristina Aguayo
Cristina Aguayo
SHSusana Hernandez
Susana Hernandez
GGGerardo Gutiérrez-Gutiérrez
Gerardo Gutiérrez-Gutiérrez
ECEnrique Casado-Sáenz
Enrique Casado-Sáenz
Malignant fibrous histiocytoma is an aggressive tumor, the most common soft-tissue sarcoma of adult age. It is usually located in the extremities and retroperitoneum, and very rarely there is skeletal involvement. Surgery is the preferred treatment in early disease; in advanced disease, chemotherapy is the main therapeutic strategy. We present a 25-year-old female patient diagnosed with a vertebral mass in T5 with a severely compromised spinal cord. She underwent surgical decompression and the pathological findings were consistent with malignant fibrous histiocytoma. After several surgical treatments she had pulmonary progression and was therefore started on chemotherapy. She had a very poor response to most of the administered regimens until she initiated trabectedin 1 mg/m2 every three weeks. She showed a significant improvement with a major response of the lung metastases. This report indicates that trabectedin is an active drug in advanced, previously treated metastatic malignant fibrous histiocytoma.

19 November 2024 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
AMAndres J. Muñoz Martín
Andres J. Muñoz Martín
RLRamón Lecumberri
Ramón Lecumberri
JSJuan Carlos Souto
Juan Carlos Souto
BOBerta Obispo
Berta Obispo
ASAntonio Sanchez
Antonio Sanchez
MHMiguel Ángel Hernández-Presa
Miguel Ángel Hernández-Presa

20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SRSilvia Roa
Silvia Roa
ALAna López-Alfonso
Ana López-Alfonso
IAInmaculada Toboso del Amo
Inmaculada Toboso del Amo
SFSandra Falagan
Sandra Falagan
FZFrancisco Zambrana
Francisco Zambrana
MSMaría Sereno
María Sereno
E15012Background: Antinuclear antibodies (ANAs) constitute a spectrum of autoantibodies targeted to nuclear and cytoplasmic components of the cells considered serological markers for different auto...